Send to

Choose Destination
See comment in PubMed Commons below
Egypt J Immunol. 2009;16(2):95-106.

Dendritic cells-based T-cell immune response for the variable region of immunoglobulin light chain of myeloma and lymphoma cell lines.

Author information

Zoology Department, Faculty of Science, Ain Shams University, Cairo, Egypt


The present work supported and extended a previous study (used VLIg gene segment type VkappaIV) and indicated that a considerable (P<0.001) and specific autologous T-cell proliferation, proliferative index (PI) ranged from 386.0 to 399.5 at 20% dendritic cells (DCs):T-cells ratio, restricted mainly (>80%) to the major histocompatibility complex (MHC) class-I molecules can be elicited in vitro against other different VLg gene segments (VkappaI, VkappaIII and Vlambda2) of myeloma and lymphoma cell lines through a retroviral transduction of human DCs generated from CD34+ progenitor cells by phorbol ester (PMA) and under serum-free conditions. This study also showed a lesser proliferation, but significant (P<0.05), restricted to MHC class-II molecules and specific for VLIg gene segments. The obtained proliferation was almost completely blocked (approximately 95%, P<0.001) by anti-CD86 monoclonal antibodies, which confirmed the critical role of the CD86 costimulatory molecules in the activation of naive T-cells. The resulting immune responses did not significantly differ (P>0.05) among the different types of VLIg gene segments, as VLIg-transduced DCs equally coexpressed the VLIg genes and CD86 costimulatory molecules. In conclusion, the present study could provide the basis of a VLIg-based immunotherapy in plasma cell and B-cell malignancies.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center